Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04499534 · ClinicalTrials.gov registry record
BRCA1/2 Flu Vaccine
A clinical trial of BRCA1 Mutation and BRCA2 Mutation, sponsored by Abramson Cancer Center at Penn Medicine.
- Active
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT04499534 is a study of BRCA1 Mutation and BRCA2 Mutation that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 50 participants, below the 574-participant average among 15 other BRCA1 Mutation trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04499534, a study of BRCA1 Mutation and BRCA2 Mutation, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate immune function in BRCA1/2 mutation carriers without cancer, specifically to determine whether immune function in healthy individuals with germline loss of function BRCA1/2 mutations, impacts overall immune health and fitness.
Conditions Studied
Interventions
- BIOLOGICAL Seasonal influenza vaccine
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2019-10-28 |
| Est. Completion | 2026-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04499534
The ClinicalTrials.gov registry entry for NCT04499534 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 574-participant average among 15 other BRCA1 Mutation trials with a reported enrollment target (91% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with BRCA1 Mutation appearing as the primary indexed condition, and to 1 intervention - of which Seasonal influenza vaccine is the first listed.
NCT04499534 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04499534 about?
NCT04499534 is a clinical study titled "BRCA1/2 Flu Vaccine". To evaluate immune function in BRCA1/2 mutation carriers without cancer, specifically to determine whether immune function in healthy individuals with germline loss of function BRCA1/2 mutations, impacts overall immune health and fitness.
What is the current status of trial NCT04499534?
This trial is currently active not recruiting. The enrollment target is 50 participants. The study started on 2019-10-28. Estimated completion is 2026-06.
What conditions does trial NCT04499534 study?
This clinical trial studies the following conditions: BRCA1 Mutation, BRCA2 Mutation.
What interventions are being tested in trial NCT04499534?
The interventions under investigation include: Seasonal influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04499534?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04499534 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for BRCA1 Mutation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results
RECRUITING · NA
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
Combination Therapy in Cancers With Mutations in DNA Repair Genes
RECRUITING · Phase 1
-
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
RECRUITING · Phase 1
-
Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.